Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.39 | -0.68 | -0.18 | 0.50 |
| FCF Yield | -3.19% | -6.26% | -8.46% | -1.99% |
| EV / EBITDA | 5.35 | 2.96 | 2.00 | 1.75 |
| Quality | ||||
| ROIC | 2.43% | 4.76% | 6.39% | 8.67% |
| Gross Margin | 17.06% | 20.98% | 22.91% | 26.36% |
| Cash Conversion Ratio | 3.09 | 1.23 | 0.82 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.94% | 2.56% | -2.53% | -1.15% |
| Free Cash Flow Growth | 12.52% | 21.91% | -285.95% | 68.90% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | 0.76 | 0.15 | -0.09 |
| Interest Coverage | 21.31 | 94.98 | 433.92 | 728.11 |
| Efficiency | ||||
| Inventory Turnover | 2.28 | 1.77 | 1.91 | 1.90 |
| Cash Conversion Cycle | 234.14 | 240.26 | 287.77 | 276.17 |